MGF Peptide: What the Research Shows

For laboratory and research use only. This product is not intended for human consumption, veterinary use, or medical applications. See our disclaimer.

Mechano Growth Factor — commonly referred to as MGF peptide — is among the more extensively characterized splice variants in the IGF-1 family, drawing sustained attention from researchers studying skeletal muscle biology, tissue repair, and neuroprotection. Unlike its parent molecule IGF-1, MGF displays a distinct C-terminal peptide sequence that confers receptor binding properties studied separately within preclinical models. For laboratories building out their research compound inventory, understanding MGF’s molecular profile and the landscape of published investigation is a foundational step before any experimental design work begins.

What Is MGF peptide?

MGF (Mechano Growth Factor), also designated IGF-1Ec in the scientific literature, is a splice variant of insulin-like growth factor 1 (IGF-1) produced in mechanically loaded tissues — most notably skeletal muscle. The splice variant differs from the systemic IGF-1 isoform through an 18-amino-acid C-terminal peptide extension (the E-domain), which is cleaved post-translationally and is proposed to signal through mechanisms distinct from the IGF-1 receptor pathway.

• CAS Number: 448938-87-2
• Molecular Weight: Approximately 2,867 Da (E-domain peptide form)
• Classification: Endogenous peptide; IGF-1 splice variant
• Research synonym: IGF-1Ec

The E-domain peptide is the fragment most commonly synthesized for in vitro and in vivo preclinical research. Its proposed mechanism of action — independent of the classical IGF-1 receptor — has made it a subject of interest in contexts where IGF-1 receptor-mediated signaling is already saturated or where researchers seek to investigate parallel growth-promoting or reparative signaling arms.

Published Research Landscape

Skeletal Muscle Satellite Cell Activation

The most-cited research area for MGF involves its proposed role in activating muscle satellite cells — the resident progenitor population responsible for skeletal muscle repair. Published preclinical work documented that mechanical loading of muscle tissue stimulates MGF splice variant expression and is associated with satellite cell proliferation in animal models. This line of investigation has been studied in the context of muscle fiber repair following mechanical strain, with MGF expression patterns documented in both rodent and human biopsy tissue under loading conditions.

Tissue Regeneration Research

Beyond skeletal muscle, MGF has been researched in the context of connective tissue and cardiac muscle repair in preclinical models. Studies have examined MGF E-domain peptide administration in animal models of myocardial injury, with researchers investigating whether satellite cell-like progenitor populations in cardiac tissue respond to exogenous MGF E-domain in patterns analogous to those observed in skeletal muscle.

Neuroprotection

A separate body of preclinical literature has examined MGF in neurological contexts. Researchers have studied the E-domain peptide in animal models of neuronal stress and injury, with some in vitro work examining proposed neuroprotective signaling at the cellular level. This area of investigation remains early-stage and largely confined to in vitro and rodent model work.

Aging and Tissue Maintenance Models

The age-related decline of MGF expression in skeletal muscle has been documented in human biopsy studies and examined as a potential contributor to the reduction in regenerative capacity observed in aged muscle. Researchers studying sarcopenia-related biology have referenced MGF expression data as part of broader investigations into IGF-1 isoform profiles across the lifespan.

Mechanism of Action

The proposed mechanism of MGF action centers on the C-terminal E-domain peptide’s capacity to interact with receptors or binding proteins distinct from the canonical IGF-1 receptor. Research models have proposed that the MGF E-domain may activate satellite cells through an IGF-1R-independent pathway, potentially involving interaction with heparan sulfate proteoglycans or other cell-surface binding partners — though the precise molecular target has not been definitively characterized across the published literature.

Researchers should note that all mechanistic claims in the published literature are derived from in vitro cell culture systems and in vivo rodent models. Extrapolation to human physiology is not supported by controlled clinical evidence at this time.

Neurovia MGF — Supply Format for Research

Neurovia supplies MGF as a lyophilized peptide for laboratory use, presented as a 5mg research vial with a verified purity of 99% by HPLC analysis. Each batch is accompanied by a Certificate of Analysis (COA) confirming identity and purity data prior to dispatch. For laboratory and research use only.

This content is for scientific and educational purposes only. Neurovia MGF is supplied for laboratory and research use only — not intended for human consumption, veterinary use, or medical applications. No statements have been evaluated by the FDA. Not intended to diagnose, treat, cure, or prevent any disease. See our full disclaimer.

Further reading: peer-reviewed research on MGF peptide (PubMed).

Related Products

• 🛒 BPC Wolverine + MGF – 10mg / 2.5mg / 1mg
• 🛒 IGF-LR3 – 1mg